ArticleAdvances in therapy2026

FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA.

Sikander Ailawadhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.